Enovis Appoints Damien McDonald as CEO, Reaffirms Q1 Guidance

On April 2, 2025, Enovis Corporation announced the appointment of Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald will also join the Board of Directors following the Annual Meeting on May 21, 2025. He succeeds Matt Trerotola, who previously announced his retirement and will not seek re-election.

McDonald brings over 35 years of experience in the medical device industry, including his tenure as CEO of LivaNova and leadership roles at Danaher, Zimmer, and Johnson & Johnson. He is recognized for driving growth, profitability, and fostering a strong, patient-focused company culture.

The company also reaffirmed its Q1 2025 guidance, with expected revenues between $555 million and $563 million and adjusted EBITDA between $97 million and $100 million.

Lead Independent Director Sharon Wienbar praised McDonald’s leadership track record and announced she will assume the role of independent Chair following Trerotola’s departure. Enovis will address questions regarding the leadership transition during its earnings call on May 8, 2025.

Enovis is a medical technology growth company focused on innovative orthopedic and patient outcome-driven solutions. More information is available at [www.enovis.com](https://www.enovis.com).